ADAPTIMMUNE THERAPEUTICS PLC
Cash Flow Statement
| Line Item | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-21.4M | $1.0M | $-29.3M | $-41.4M | $-44.5M | $-50.3M | $-38.9M | $-42.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $2.2M | $1.7M | $1.3M | $1.3M | $1.3M | $1.4M | $1.3M | $1.5M |
| Amortization | — | — | $-3.5M | $67.0K | $78.0K | $4.2M | — | — |
| Stock-Based Compensation | $3.8M | $1.7M | $3.9M | $3.7M | $5.0M | $5.6M | $4.8M | $5.0M |
| Net Cash from Operating Activities | $-43.8M | $-37.3M | $2.0M | $-48.2M | $-41.3M | $-54.4M | $133.9M | $-45.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.2M | $2.3M | $3.4M | $10.0M | $9.0M | $7.1M | $4.0M | $1.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $2.7M | $48.3M | $21.0M | $28.9M | $44.1M | $-4.8M | $-28.5M | $34.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $14.0K | $196.0K | $1.4M | $1.5M | $10.0M | $35.0K | $52.0K | $139.0K |
| Net Change in Cash | $-41.2M | $11.8M | $28.9M | $-18.8M | $8.3M | $-60.4M | $107.0M | $-10.5M |
| Free Cash Flow | $-45.0M | $-39.6M | $-1.4M | $-58.2M | $-50.2M | $-61.5M | $129.9M | $-46.8M |